Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3121 to 3135 of 7684 results

  1. Lipid disorders: FH assessment and diagnosis (new readings) (IND261)

    This indicator covers the percentage of patients with a total cholesterol reading in the preceding 12 months greater than 7.5 mmol/litre who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM245

  2. Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)

    This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244

  3. Depression and anxiety: recovery following talking therapies (IND26)

    This indicator covers the proportion of people of all ages with depression and anxiety who clinically recover following talking therapies. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG41

  4. Stroke and ischaemic attack: register (IND259)

    This indicator covers the contractor establishing and maintaining a register of patients with stroke or transient ischaemic attack (TIA). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM243

  5. GP services: palliative care register (IND258)

    This indicator covers the contractor establishing and maintaining a register of patients in need of palliative care or support. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM242

  6. Cancer: invasive cancer diagnosed via emergency routes (IND1)

    This indicator covers the proportion of invasive cases of cancer diagnosed via an emergency route. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCC01

  7. COPD: annual review (IND191)

    This indicator covers the percentage of patients with COPD on the register, who have had a review in the preceding 12 months, including a record of the number of exacerbations and an assessment of breathlessness using the Medical Research Council dyspnoea scale. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM170

  8. COPD: register (IND190)

    This indicator covers registering patients with a clinical diagnosis of COPD before (start date), and patients with a clinical diagnosis of COPD on or after (start date) whose diagnosis has been confirmed by a quality assured post bronchodilator spirometry FEV1/FVC ratio below 0.7 between 3 months before or 3 months after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM169

  9. Pregnancy and neonates: smokers at delivery (IND19)

    This indicator covers the proportion of pregnant women who were smokers at the time of delivery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG32

  10. Asthma: smoking status (under 19) (IND189)

    This indicator covers the percentage of patients with asthma on the register aged 19 or under, in whom there is a record of smoking status (active or passive) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM168

  11. Asthma: objective tests (IND187)

    This indicator covers the percentage of patients with asthma on the register from (start date) with a record of spirometry and 1 other objective test (FeNO or reversibility or variability) between 3 months before or 3 months after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM166

  12. Asthma: register (IND186)

    This indicator covers the contractor establishing and maintaining a register of patients with asthma aged 5 or over. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM165

  13. Diabetes: statins for primary prevention of CVD (40 years and over) (IND183)

    This indicator covers the percentage of patients with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty, who are currently treated with a statin (excluding patients with type 2 diabetes and a cardiovascular disease risk score of less than 10% recorded in the preceding 3 years). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM162

  14. Diabetes: statins for primary prevention of CVD (T2DM and 10% risk) (IND182)

    This indicator covers the percentage of patients with a diagnosis of type 2 diabetes and a recorded cardiovascular disease risk assessment score of 10% or more (without moderate or severe frailty), who are currently treated with a statin (unless there is a contraindication or statin therapy is declined). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM161

  15. Diabetes: CVD risk assessment (IND181)

    This indicator covers the percentage of patients aged between 25 and 84 years, with type 2 diabetes, without moderate or severe frailty, not currently treated with a statin, who have had a consultation for a full formal cardiovascular disease risk assessment in the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM160